CClinicalTrials.gg
CompletedNCT02630160ILIACPCPTHRUpdated Oct 12, 2016

The Influence of Local Infiltration Analgesia by Catheter in Postoperative Control Pain After Total Hip Replacement

A Phase 4 interventional study of Bupivacaine hydrochloride and Physiological Saline in Musculoskeletal Pain and Hip Injuries, sponsored by Parc de Salut Mar. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-12.

Sponsored by Parc de Salut Mar · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A randomized double-blind clinical trial was performed. There were 4 groups according to catheter placement and infusion constituents: 1) Intraarticular catheter + anesthetics; 2) Intraarticular catheter +placebo; 3) Subfascial catheter + anesthetics; 4) Subfascial catheter + placebo. The anesthetics infusion contained bupivacaine (bolus + continuous perfusion up to 36 hours). The placebo solution consisted in physiological serum (bolus + continuous perfusion up to 36 hours). Randomization was performed in the hospital pharmacy and the surgeon kept out the surgical field when the resident placed the catheter. The same conventional analgesic schedule was prescribed to all patients: PCA (patient controlled analgesia) + paracetamol 1g/6h + dexketoprofen 50mg/12h. The pain was evaluated by means of PCA (patient controlled analgesia) shots and the VAS (visual analog scale). Side effects, time to start rehabilitation and time to discharge were also analyzed. A statistical analysis was performed to compare all this variables between the 4 groups (SPSS 18.0).

02

Conditions studied

  • Musculoskeletal Pain
  • Hip Injuries
03

In context

Musculoskeletal Pain

493 studies on the registry are indexed under Musculoskeletal Pain; 114 are open to participants now.

This study's enrollment of 100 is above the median of 69 across 346 interventional studies indexed under Musculoskeletal Pain.

Browse Musculoskeletal Pain studies →

Lead sponsor

Parc de Salut Mar is the lead sponsor of 180 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Primary total Hip Replacement

Exclusion criteria

Exclusion Criteria:

  • Allergic to Bupivacaine
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Intraarticular Catheter with anesthesic

    Intraarticular infusion with Bupivacaine Hydrochloride

    Drug: Bupivacaine hydrochloride

  • Placebo comparator
    Intraarticular Physiological Saline

    Infusion of Physiological Saline \[Flebobag Salina Fisiologica Grifols 0.9%\] Sterile Solution by intraarticular catheter

    Other: Physiological Saline

  • Active comparator
    Perifascial Catheter with anesthesic

    Perifascial infusion with Bupivacaine Hydrochloride

    Drug: Bupivacaine hydrochloride

  • Placebo comparator
    Perifascial Physiological Saline

    Infusion of Physiological Saline \[Flebobag Salina Fisiologica Grifols 0.9%\] Sterile Solution by Perifascial catheter

    Other: Physiological Saline

Interventions

  • DrugBupivacaine hydrochloride

    Intraarticular infusion with bupivacaine

    Also known as: Bupivacaine / epinephrine, Vivacaine

  • OtherPhysiological Saline

    Intraarticular infusion physiological serum

    Also known as: Flebobag Salina Fisiologica Grifols 0.9%

06

What researchers measure

Primary outcomes

  1. Change in pain measured with a visual analog scale

    Visual analog pain scale score every eight hours for 36 hours postoperatively

    Time frame: 36 hours

07

Study locations

1 site
  • Hospital del Mar
    Barcelona, 08003, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02630160
Lead sponsor
Parc de Salut Mar
Responsible party
Daniel Pérez Prieto (MD, Parc de Salut Mar) — Principal investigator
First posted
Dec 15, 2015
Start date
Mar 2013
Primary completion
May 2014
Completion
Jun 2014
Last update
Oct 12, 2016

Study contacts

Daniel Pérez Prieto
principal investigator · Hospital del Mar
Marta Cuenca Llavall
study chair · Hospital del Mar
Fernando Marques Lopez
study director · Hospital del Mar
Alfonso Leon Garcia
study chair · Hospital del Mar
Francisco Javier Santiveri Papiol
study chair · Hospital del Mar

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion